Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity

doi:10.3969/j.issn.1673-8640.2023.04.007

Abstract

Abstract:

Objective To investigate the expression level of microRNA-433（miR-433） in patients with endometrial cancer and its relationship with chemotherapy sensitivity. Methods From May 2019 to July 2020，98 endometrial cancer patients in Nanyang Central Hospital were enrolled as endometrial cancer group. The clinical data were collected. According to the determination of sensitivity after 4 cycles of chemotherapy，the patients with endometrial cancer were classified into sensitive group（79 cases） and insensitive group（19 cases）. Tumor tissues and paracancer tissues （3 cm from the edge of tumors）removed after chemotherapy were collected. Real-time fluorescence quantitative polymerase chain reaction（RT-qPCR） was used to determine the expression level of miR-433. Multiple Logistic regression analysis was used to analyze the factors affecting the chemotherapy sensitivity of endometrial cancer. Results Compared with adjacent tissue，the expression level of miR-433 in endometrial cancer tissue was lower（P<0.05）. The expression level of miR-433 in patients with the International Federation of Gynecology and Obstetrics（FIGO） stage Ⅲ-Ⅳ，lymph metastasis and low differentiated endometrial cancer was lower than that in patients with FIGO stage Ⅰ-Ⅱ，non-lymph metastasis and medium/high differentiated endometrial cancer（P<0.05）. Compared with sensitive group，the expression level of miR-433 in insensitive group was decreased（P<0.05）. Tumor diameter，FIGO stage，lymph metastasis and the degree of tissue differentiation were related to chemotherapy sensitivity（P<0.05）. Multiple Logistic regression analysis showed that FIGO stage and miR-433 relative expression level were risk factors affecting the chemotherapy sensitivity of endometrial cancer [odds ratios（OR） were 2.716 and 0.847，95% confidence intervals（CI） were 1.420-5.196 and 0.766-0.936，respectively]. Conclusions MiR-433 is low-expressed in endometrial cancer tissues，which is a factor affecting chemotherapy sensitivity.

Key words: MicroRNA-433, Endometrial cancer, Chemotherapy sensitivity

CLC Number:

R446.1

YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity[J]. Laboratory Medicine, 2023, 38(4): 337-341.

Figures/Tables 6

References 15.

1.	SVANVIK T, MARCICKIEWICZ J, SUNDFELDT K, et al. Sociodemographic disparities in stage-specific incidences of endometrial cancer:a registry-based study in West Sweden,1995-2016[J]. Acta Oncol, 2019, 58(6):845-851. DOI URL
2.	马丽娜, 孙笑, 王丽华. 1型胰岛素样生长因子受体和表皮生长因子受体在子宫内膜癌中的临床价值[J]. 检验医学, 2019, 34(10):918-922.
3.	SHANG C, AO C N, CHEONG C C, et al. Long non-coding RNA CDKN2B antisense RNA 1 gene contributes to paclitaxel resistance in endometrial carcinoma[J]. Front Oncol, 2019, 9:27. DOI PMID
4.	郭珍珍, 尹瑞雪, 田小飞. miRNA与女性生殖系统肿瘤的研究进展[J]. 世界最新医学信息文摘, 2019, 19(76):123-125.
5.	隋守光, 赵素伟, 路建宽, 等. 肝癌组织中miR-433表达及其对多西他赛化疗耐药的机制研究[J]. 中国临床药理学杂志, 2020, 36(11):1507-1510.
6.	WERNER H M, TROVIK J, MARCICKIEWICZ J, et al. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification[J]. Gynecol Oncol, 2012, 125(1):103-108. DOI PMID
7.	THERASSE P, ARBUCK S G, EISENHAUER E A, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3):205-216. DOI URL
8.	WESTIN S N, FELLMAN B, SUN C C, et al. Prospective phase Ⅱ trial of levonorgestrel intrauterine device:nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer[J]. Am J Obstet Gynecol, 2021, 224(2):191.e1-191.e15.
9.	游兴文, 管华平, 王艳虹, 等. 放化疗联合应用对高危子宫内膜癌患者血清肿瘤标志物水平及预后的影响[J]. 癌症进展, 2020, 18(1):48-50.
10.	CASTELLANO T, JOHN MAXWELL I V, ADAM WALTER J, et al. Phase Ⅱ trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched,high-intermediate risk factors for recurrence[J]. Gynecol Oncol, 2021, 160(3):669-673. DOI URL
11.	SUN R, LIU J, NIE S, et al. Construction of miRNA-mRNA regulatory network and prognostic signature in endometrial cancer[J]. Onco Targets Ther, 2021, 14:2363-2378. DOI URL
12.	WANG Q, XU K, TONG Y, et al. Novel miRNA markers for the diagnosis and prognosis of endometrial cancer[J]. J Cell Mol Med, 2020, 24(8):4533-4546. DOI PMID
13.	黄蓉, 王云飞, 杨飞, 等. MicroRNA在子宫内膜癌中的调控作用[J]. 世界最新医学信息文摘, 2020, 20(19):2.
14.	胡晓磊, 黄萍妹, 王洁, 等. MiR433靶向调控Notch1逆转人乳腺癌细胞对多西他赛的耐药性[J]. 南方医科大学学报, 2018, 38(7):888-894.
15.	JIN L, ZHANG N, ZHANG Q, et al. Serum microRNAs as potential new biomarkers for cisplatin resistance in gastric cancer patients[J]. PeerJ, 2020, 8:e8943. DOI URL

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
miR-433	CGCAGGAGTGGCTGTGCG	CGCGATACCTGTCCAGCAGTG
U6	GCCATGGCAGTACTCTCGTGC	TGCAGTCACAGCTGTCCGCTG

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
miR-433	CGCAGGAGTGGCTGTGCG	CGCGATACCTGTCCAGCAGTG
U6	GCCATGGCAGTACTCTCGTGC	TGCAGTCACAGCTGTCCGCTG

临床病理特征	例数	miR-433相对表达量
年龄
<60岁	57	0.67±0.18
≥60岁	41	0.69±0.17
t值		0.555
P值		0.580
绝经
是	60	0.68±0.16
否	38	0.67±0.17
t值		0.294
P值		0.769
肿瘤直径
<5 cm	44	0.70±0.21
≥5 cm	54	0.66±0.18
t值		1.015
P值		0.313
肌层浸润
<1/2	46	0.69±0.18
≥1/2	52	0.67±0.19
t值		0.533
P值		0.595
FIGO分期
Ⅰ~Ⅱ	49	0.73±0.14
Ⅲ~Ⅳ	49	0.63±0.15
t值		3.412
P值		0.001
病理类型
浆液性腺癌	52	0.70±0.17
子宫内膜样腺癌	46	0.65±0.16
t值		1.494
P值		0.139
淋巴转移
有	53	0.62±0.14
无	45	0.75±0.21
t值		3.653
P值		0.000
组织分化程度
中/高分化	42	0.76±0.19
低分化	56	0.62±0.15
t值		4.076
P值		0.000

临床病理特征	例数	miR-433相对表达量
年龄
<60岁	57	0.67±0.18
≥60岁	41	0.69±0.17
t值		0.555
P值		0.580
绝经
是	60	0.68±0.16
否	38	0.67±0.17
t值		0.294
P值		0.769
肿瘤直径
<5 cm	44	0.70±0.21
≥5 cm	54	0.66±0.18
t值		1.015
P值		0.313
肌层浸润
<1/2	46	0.69±0.18
≥1/2	52	0.67±0.19
t值		0.533
P值		0.595
FIGO分期
Ⅰ~Ⅱ	49	0.73±0.14
Ⅲ~Ⅳ	49	0.63±0.15
t值		3.412
P值		0.001
病理类型
浆液性腺癌	52	0.70±0.17
子宫内膜样腺癌	46	0.65±0.16
t值		1.494
P值		0.139
淋巴转移
有	53	0.62±0.14
无	45	0.75±0.21
t值		3.653
P值		0.000
组织分化程度
中/高分化	42	0.76±0.19
低分化	56	0.62±0.15
t值		4.076
P值		0.000

组别	例数	年龄				绝经			肿瘤直径		肌层浸润
组别	例数	<60岁/ [例（%）]		≥60岁/ [例（%）]		否/ [例（%）]	是/ [例（%）]		<5.0 cm/ [例（%）]	≥5.0 cm/[例（%）]	<1/2/ [例（%）]		≥1/2/ [例（%）]
化疗敏感组	79	47（82.46）		32（78.05）		30（78.94）	49（81.67）		41（93.18）	38（70.37）	37（80.43）		42（80.77）
化疗不敏感组	19	10（17.54）		9（21.95）		8（21.05）	11（18.33）		3（6.82）	16（29.63）	9（19.57）		10（19.23）
χ²值		0.296				0.110			8.072		0.002
P值		0.586				0.740			0.004		0.967
组别	FIGO分期				病理类型					淋巴转移		组织分化程度
组别	Ⅰ~Ⅱ期/ [例（%）]		Ⅲ~Ⅳ期/ [例（%）]		浆液性腺癌/[例（%）]			子宫内膜样腺癌/[例（%）]		无/ [例（%）]	有/ [例（%）]	中或高分化/ [例（%）]		低分化/ [例（%）]
化疗敏感组	45（91.84）		34（69.39）		43（82.69）			36（78.26）		42（93.33）	37（69.81）	39（92.86）		40（71.43）
化疗不敏感组	4（8.16）		15（30.61）		9（17.31）			10（21.74）		3（6.67）	16（30.19）	3（7.14）		16（28.57）
χ²值	7.900				0.307					8.616		7.051
P值	0.005				0.580					0.003		0.008